TEL AVIV, Israel, April 6, 2015 (GLOBE NEWSWIRE) — Alcobra Ltd. (ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that corporate presentations will be provided at two conferences focused on Central Nervous System (CNS) disorders in April.
|10th Annual Neurotech Investing & Partnering Conference|
|Date:||Tuesday, April 7|
|Time:||3:30pm Pacific Time|
|Location:||Hotel Nikko, San Francisco|
|Presenter:||David Baker, Chief Commercial Officer|
|Neurology Innovation Conference|
|Date:||Sunday, April 19|
|Time:||3:30pm Eastern Time|
|Location:||Embassy Suites, Washington DC|
|Presenter:||Jonathan Rubin, MD, MBA, Chief Medical Officer|
About Alcobra Ltd.
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome. MDX has completed multiple Phase II studies and a Phase III study in adults with ADHD. The company is conducting separate Phase II trials in pediatric ADHD and in Fragile X Syndrome. For more information please visit the Company’s website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.
U.S. Investor Contacts LifeSci Advisors, LLC Michael Rice 646-597-6979 email@example.com Media Inquiries Sam Brown, Inc. Mike Beyer 773-463-4211 firstname.lastname@example.org Israel Investor Contact: Alcobra Investor Relations Debbie Kaye +972-72 2204661 email@example.com